4D MOLECULAR THERAPEUTICS INC. - COMMON STOCK

4DMT Provides Company Update and Anticipated Development Milestones for 2026

07 Jan 2026 05:00:00 By Nasdaq GlobeNewswire

4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease

17 Dec 2025 04:00:00 By Nasdaq GlobeNewswire

4DMT Announces New Employment Inducement Grants

12 Dec 2025 13:05:00 By Nasdaq GlobeNewswire

4DMT to Participate in 8th Annual Evercore Healthcare Conference

20 Nov 2025 05:00:01 By Nasdaq GlobeNewswire

4DMT Appoints Kristian Humer as Chief Financial Officer

17 Nov 2025 03:00:00 By Nasdaq GlobeNewswire

4DMT Announces New Employment Inducement Grants

14 Nov 2025 13:05:00 By Nasdaq GlobeNewswire

4DMT Reports Third Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

10 Nov 2025 05:00:01 By Nasdaq GlobeNewswire

4DMT to Participate in Jefferies 2025 London Healthcare Conference

06 Nov 2025 13:05:02 By Nasdaq GlobeNewswire

4DMT Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants

06 Nov 2025 03:23:59 By Nasdaq GlobeNewswire

4DMT Announces Positive Long-Term Data from Phase 1/2 PRISM Clinical Trial in Wet AMD Supporting 4D-150’s Potential as a Backbone Therapy with Consistent and Durable Benefit over Multiple Years

06 Nov 2025 03:00:00 By Nasdaq GlobeNewswire

4DMT Announces Exclusive License Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of 4D-150 in Asia-Pacific

30 Oct 2025 20:02:12 By Nasdaq GlobeNewswire

4DMT Announces New Employment Inducement Grants

17 Oct 2025 13:05:00 By Nasdaq GlobeNewswire

4DMT to Participate in Chardan's 9th Annual Genetic Medicines Conference

14 Oct 2025 05:00:51 By Nasdaq GlobeNewswire

4DMT Advances 4D-710 to Phase 2 with Additional Funding and Support from the Cystic Fibrosis Foundation

13 Oct 2025 05:00:00 By Nasdaq GlobeNewswire

4DMT Announces New Employment Inducement Grants

12 Sep 2025 13:05:00 By Nasdaq GlobeNewswire

4DMT Announces Leadership Expansion with Proven Late-Stage Executives to Drive 4D-150 Execution and BLA Readiness

02 Sep 2025 05:00:00 By Nasdaq GlobeNewswire

4DMT to Participate in Upcoming Investor Conferences

25 Aug 2025 05:00:01 By Nasdaq GlobeNewswire

4DMT Announces New Employment Inducement Grants

15 Aug 2025 13:05:00 By Nasdaq GlobeNewswire

4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

11 Aug 2025 05:00:00 By Nasdaq GlobeNewswire

4DMT to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

06 Aug 2025 05:00:00 By Nasdaq GlobeNewswire